Acutaas Chemicals Ltd

Acutaas Chemical Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Acutaas Chemicals Ltd

₹ 3,495 2.78%
13 Jul 4:04 p.m.
amiorganics.com BSE: 543349 NSE: ACUTAAS
About

Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals and fine chemicals.[1]

Key Points

Business Overview [1] [2]
The company is a specialty chemicals manufacturer with a diversified portfolio of over 610 products, serving industries such as pharmaceuticals, semiconductors, battery chemicals, personal care, agrochemicals, and fine chemicals. Its core expertise lies in the research-driven development and manufacturing of advanced pharmaceutical intermediates for regulated and generic APIs, as well as intermediates for New Chemical Entities (NCEs). It is also expanding into high-value specialty chemicals catering to emerging applications, including battery materials, semiconductors, and next-generation electronics.

Website BSE NSE
  • Market Cap ₹ 28,616 Cr.
  • Current Price ₹ 3,495
  • High / Low ₹ 3,740 / 1,124
  • Stock P/E 78.1
  • Book Value ₹ 204
  • Dividend Yield 0.04 %
  • ROCE 32.8 %
  • ROE 24.6 %
  • Face Value ₹ 5.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 46.3% CAGR over last 5 years

Cons

  • Stock is trading at 16.9 times its book value
  • Promoter holding has decreased over last 3 years: -6.75%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 Nifty500 Shariah Nifty Alpha 50

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
186 142 164 162 220 171 244 271 304 206 305 391 422
146 117 145 138 180 145 195 204 220 155 209 237 241
Operating Profit 41 25 19 24 40 26 48 67 84 51 97 154 181
OPM % 22% 18% 11% 15% 18% 15% 20% 25% 28% 25% 32% 39% 43%
-0 1 -30 3 9 2 9 2 6 16 9 6 15
Interest 1 1 1 3 2 4 0 1 0 1 1 1 1
Depreciation 3 3 3 4 4 6 6 6 7 7 8 9 9
Profit before tax 37 23 -16 20 42 18 50 63 83 59 97 151 186
Tax % 26% 25% 31% 23% 24% 25% 25% 28% 24% 24% 25% 26% 26%
27 17 -21 16 32 14 38 45 63 45 73 112 137
EPS in Rs 3.73 2.31 -2.84 2.13 4.35 1.68 4.60 5.53 7.67 5.45 8.90 13.63 16.74
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
160 188 236 240 341 520 617 688 990 1,324
137 158 193 198 259 415 493 580 765 841
Operating Profit 23 31 43 42 81 105 123 108 225 483
OPM % 14% 16% 18% 18% 24% 20% 20% 16% 23% 36%
0 3 1 2 0 3 4 -18 18 46
Interest 3 3 5 6 6 6 2 6 6 3
Depreciation 1 2 3 4 4 10 12 15 24 33
Profit before tax 19 28 37 35 72 91 112 69 214 493
Tax % 35% 35% 33% 21% 25% 21% 26% 37% 25% 26%
12 18 25 27 54 72 83 44 160 366
EPS in Rs 40.17 61.43 11.73 13.08 8.57 9.87 11.43 5.92 19.48 44.73
Dividend Payout % 0% 0% 0% 0% 0% 15% 13% 25% 8% 6%
Compounded Sales Growth
10 Years: %
5 Years: 31%
3 Years: 29%
TTM: 34%
Compounded Profit Growth
10 Years: %
5 Years: 46%
3 Years: 63%
TTM: 132%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: 79%
1 Year: 197%
Return on Equity
10 Years: 20%
5 Years: 18%
3 Years: 19%
Last Year: 25%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 2 2 10 10 32 36 36 37 41 41
Reserves 38 56 71 97 132 482 550 638 1,271 1,627
26 41 54 59 137 1 3 203 11 32
43 56 77 61 110 136 169 193 215 235
Total Liabilities 109 155 212 228 410 655 759 1,071 1,538 1,935
14 15 58 62 161 178 222 357 499 601
CWIP 11 30 2 12 0 3 30 125 130 228
Investments 15 21 28 28 33 33 33 68 70 118
68 89 124 126 216 440 474 521 839 989
Total Assets 109 155 212 228 410 655 759 1,071 1,538 1,935

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
29 10 22 27 26 -10 56 101 116 305
-19 -27 -25 -24 -100 -122 -20 -337 -234 -334
-7 14 3 0 72 140 -14 235 274 4
Net Cash Flow 2 -2 -0 3 -2 8 21 -1 155 -25
Free Cash Flow 14 -17 4 8 -75 -42 -28 -205 -75 110
CFO/OP 154% 58% 83% 85% 50% 12% 65% 109% 71% 86%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 83 97 113 80 127 113 136 113 107 99
Inventory Days 76 89 95 148 123 150 131 135 116 147
Days Payable 148 154 168 146 172 158 153 119 104 98
Cash Conversion Cycle 11 31 40 83 78 105 114 129 119 149
Working Capital Days 46 59 23 29 49 139 138 89 122 116
ROCE % 38% 35% 27% 33% 24% 21% 14% 20% 33%

Insights

In beta
Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Export Share of Revenue
%

Log in to view insights

Please log in to see hidden values.

Login
Pharmaceutical Intermediates Revenue Share
%
Number of Countries Served
count
Number of Customers
count
Number of Products Invoiced
count
Process Patents
count
Total Installed Capacity
KL

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

2 Recently
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
39.41% 38.93% 39.91% 39.91% 35.98% 35.97% 35.96% 35.96% 32.66% 32.66% 32.66% 32.66%
6.73% 7.15% 11.66% 8.98% 12.93% 13.87% 15.52% 16.48% 16.94% 16.84% 16.67% 19.48%
5.12% 5.95% 7.58% 6.80% 14.81% 19.93% 20.23% 18.31% 22.38% 22.59% 21.70% 19.60%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
48.74% 47.97% 40.85% 44.31% 36.28% 30.24% 28.27% 29.22% 28.00% 27.89% 28.96% 28.24%
No. of Shareholders 70,35272,89783,34495,78490,98793,39495,7561,14,0601,19,8901,08,6641,10,3631,12,939

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls